$9.83 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter

Wall Street brokerages forecast that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report $9.83 million in sales for the current quarter, Zacks reports. Five analysts have issued estimates for BioDelivery Sciences International’s earnings, with the highest sales estimate coming in at $10.93 million and the lowest estimate coming in at $8.99 million. BioDelivery Sciences International posted sales of $3.93 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 150.1%. The company is expected to report its next earnings results on Friday, March 16th.

On average, analysts expect that BioDelivery Sciences International will report full year sales of $9.83 million for the current year, with estimates ranging from $37.01 million to $60.40 million. For the next fiscal year, analysts forecast that the company will post sales of $47.29 million per share, with estimates ranging from $42.70 million to $54.67 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover BioDelivery Sciences International.

Several research firms have recently commented on BDSI. Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Sunday, October 22nd. Roth Capital set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 13th. Seaport Global Securities began coverage on shares of BioDelivery Sciences International in a research report on Friday, January 26th. They set a “buy” rating and a $5.00 price target on the stock. Zacks Investment Research raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, HC Wainwright set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. BioDelivery Sciences International presently has an average rating of “Buy” and an average price target of $4.38.

BioDelivery Sciences International (NASDAQ:BDSI) traded down $0.23 during mid-day trading on Monday, hitting $2.17. 476,800 shares of the stock traded hands, compared to its average volume of 556,475. The stock has a market cap of $134.12, a price-to-earnings ratio of -11.41 and a beta of 0.50. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International has a 1 year low of $1.55 and a 1 year high of $3.60.

In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 108,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total value of $277,560.00. Following the sale, the director now owns 1,759,262 shares of the company’s stock, valued at $4,521,303.34. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark A. Sirgo sold 709,502 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $2.73, for a total value of $1,936,940.46. Following the completion of the sale, the director now directly owns 1,759,262 shares in the company, valued at approximately $4,802,785.26. The disclosure for this sale can be found here. In the last three months, insiders sold 980,011 shares of company stock worth $2,666,275. 9.00% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in BDSI. Wells Fargo & Company MN raised its position in BioDelivery Sciences International by 138.2% in the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,599 shares during the period. JPMorgan Chase & Co. purchased a new stake in BioDelivery Sciences International in the third quarter valued at approximately $116,000. Advisor Group Inc. raised its position in BioDelivery Sciences International by 42.1% in the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 13,341 shares during the period. Two Sigma Investments LP purchased a new stake in BioDelivery Sciences International in the fourth quarter valued at approximately $166,000. Finally, BlueCrest Capital Management Ltd purchased a new stake in BioDelivery Sciences International in the fourth quarter valued at approximately $201,000. 44.16% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “$9.83 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/15/9-83-million-in-sales-expected-for-biodelivery-sciences-international-inc-bdsi-this-quarter.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply